Pre admission treatment with Beta-blockers in hypertensive patients with acute stroke and 3-month outcomeData from a national stroke registry
Pre admission treatment with Beta-blockers in hypertensive patients with acute stroke and 3-month outcomeData from a national stroke registry
复制标题
DOI：
10.1111/jch.13211
复制
发表时间：
2018-03-01
影响因子：
2.8
通讯作者：
Koton, Silvia
中科院分区：
文献类型：
--
作者：
Eizenberg, Yoav;Grossman, Ehud;Koton, Silvia
β-受体阻滞剂(BB)治疗对卒中结局的影响尚不清楚。我们使用来自一项预期的全国卒中登记的数据来评估BB的使用与卒中后3个月预后不良之间的关系。使用以色列国家急性卒中(NASIS)登记，我们确定了1126名接受卒中前高血压治疗的缺血性卒中和脑内出血患者，并对其进行了3个月的跟踪调查。在调整人口学和临床因素的情况下，采用BB量表比较3个月时的功能结局和死亡率。有615名(54.6%)患者报告在卒中前使用了BB。使用BB的患者显示出更高的房颤、心脏病、他汀类药物使用、癌症和严重中风的发生率。卒中后3个月，BB使用者与非BB使用者相比，调整的优势比(OR)为0.86(0.49-1.52)，Barthel指数60为1.07(0.76-1.50)。总而言之，使用BB治疗与高血压患者3个月的不良结局无关。
The impact of beta-blockers (BB) treatment on stroke outcome is unclear. We used data from a prospective national stroke registry to assess the associations between use of BB and poor outcome 3months after stroke. Using the National Acute Stroke Israeli (NASIS) registry, we identified 1126 patients with ischemic stroke and intracerebral hemorrhage with pre-stroke hypertension treatment, who were followed for 3-months. Functional outcome and mortality at 3-month were compared by use of BB, adjusting for demographics and clinical factors. Pre-stroke use of BB was reported by 615 (54.6%) patients. Users of BB showed higher rates of atrial fibrillation, heart disease, statin use, cancer, and severe stroke. Adjusted odds-ratios (ORs, 95% CI) for BB users compared with non-users 3months after stroke were 0.86 (0.49-1.52) for mortality and 1.07 (0.76-1.50) for Barthel Index 60. In conclusion, treatment with BB is not associated with 3-month poor outcome in hypertensive patients.